Some features may not work as expected in this browser. For the full NewsNow experience, please consider updating your browser or trying a different device. Some features may not work as expected.
Please consider updating your browser or device.

You’re on our free ad-supported tier. Upgrade to NewsNow Essentials for just £4/m now! Your favourite news platform, faster, slicker and ad free.You’re on our free tier. Get NewsNow Essentials at just £4/m now!. Faster, slicker and ad free.You’re on our free tier. Go ad free for just £4/m now!

Home
Hot Topics
UK
World
Gaza
Ukraine
Iran
Climate Crisis
AI
Business
Football
Sport
Entertainment
Tech
Science

AstraZeneca
Pharmaceuticals
GSK
Novartis
Novo Nordisk
Sanofi
Johnson and Johnson
Takeda
Bristol Myers Squibb
Topics

Advertisement

Advertisement

AstraZeneca

Share

Top Latest Popular

NewsNow Essentials. Better browsing, ad free. Just £4/m, billed annually. Upgrade now!

NewsNow Essentials. Your favourite news platform, ad free. £4/m, billed annually. Upgrade now!

Why is AstraZeneca stock trading higher today?

Benzinga 4d

AstraZeneca shares oversold after trial flops and merger talk, says UBS

Proactive Investors (US) 2d

Broker tips: GSK, Astrazeneca, Vodafone

ShareCast 3d

Advertisement

Advertisement

No Surprise As Serena-4 Serves Up A Miss For AstraZeneca’s Etcamah

Scrip Pharma Intelligence 4d

Tagrisso® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

Business Wire (Press Release) 4d

AstraZeneca’s Tagrisso shows eight-year landmark survival in early-stage EGFR-mutated lung cancer

PMLiVE 4d

Astrazeneca's Etcamah trial fails to meet primary endpoint

ShareCast 4d

The City analysts tipping AstraZeneca shares to rise again

interactive investor 21h

Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced Er-positive breast cancer

AstraZeneca (Press Release) 6d

Enhertu demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in destiny-Lung04 Phase III trial

AstraZeneca (Press Release) 4d

Advertisement

Advertisement

Advertisement

My Local News

Advertisement

About our AstraZeneca news

Latest news on AstraZeneca, an Anglo-Swedish multinational pharmaceutical and biotechnology company based in Cambridge, with live updates on products and research.

NewsNow

Our Sites

NewsNow Nigeria

NewsNow România

NewsNow Australia

Work with us

Publisher Network

Dockside Online IDE

Legal

Subscription Terms

© Copyright 1997 - 2026 NewsNow Publishing Limited. All rights reserved.

Back to Industry Sectors Pharmaceuticals
- Abbott Laboratories
- AbbVie AbbVie
- AstraZeneca
- Baxter Baxter
- Bayer Bayer
- Boehringer Ingelheim
- Bristol Myers Squibb
- Eli Lilly Eli Lilly
- Genentech Genentech
- GlaxoSmithKline
- Johnson and Johnson
- Merck and Co
- Novartis Novartis
- Novavax Novavax
- Novo Nordisk
- Pfizer Pfizer
- Roche Roche
- Sanofi Sanofi
- Takeda Takeda
- Teva Teva
- Zoetis Zoetis